Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Vaxdyn

Vaxdyn, Seville, Spain
www.vaxdyn.com

KAPAVAX
TRIVALENT VACCINE TO PREVENT BACTERIAL PNEUMONIA

Vaccine

By leveraging its proprietary vaccine platform based on LPS-null Acinetobacter baumannii cells, Vaxdyn seeks to develop a single, trivalent vaccine directed against the Gram-negative pathogens A. baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae.  If successful, this vaccine could address significant unmet clinical need in preventing pneumonia in adults with elevated risk (e.g., patients with chronic lung disease or diabetes, or undergoing cancer treatment).  It also has the potential to prevent neonatal infections, an issue of critical importance, in particular in low-to-middle income countries around the world, by stimulating maternal immunity in pregnant women.

Current Development Stage: Lead Optimization

CARB-X Investment: Initial investment of up to $892,000 with potential option payments up to $6.36m

Initial CARB-X Investment Date: June 1, 2019

Carb-X

Led by Boston University

Copyright 2023

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2023